#United States #New York #Rosen Law Firm #Securities Class Action #Aldeyra Therapeutics

Rosen Law Firm Launches Investigation into Aldeyra Therapeutics'

Rosen Law Firm, a prominent global investor rights law firm, has initiated an inquiry into potential securities claims concerning Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). This investigation arises amidst troubling allegations that the company may have provided misleading business information that significantly impacted shareholders.

Background of the Investigation

On March 17, 2026, Aldeyra disclosed via a Current Report on Form 8-K to the Securities and Exchange Commission that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). This letter concerns the company's New Drug Application (NDA) for reproxalap, revealing serious concerns regarding the drug's efficacy for treating dry eye disease.

The FDA's report articulated that there was a "lack of substantial evidence" supporting the claims concerning the drug's effects. It highlighted that the application failed to demonstrate adequate efficacy in well-controlled studies, raising grave doubts about the reliability of the company’s past positive findings.

As a result of this announcement, Aldeyra's stock plummeted by $2.99 per share, equivalent to a staggering 70.7% decline, closing at only $1.24 per share by the end of the trading day on March 17. The immense drop immediately highlighted the severity of the situation for investors who had relied on the previous disclosures from Aldeyra.

The Opportunity for Investors

Investors who purchased Aldeyra's securities may be entitled to pursue compensation due to the significant financial losses incurred following this announcement. The Rosen Law Firm has indicated that affected investors can join a potential class action lawsuit without any out-of-pocket expenses through a contingency fee arrangement. This means that the firm only receives payment if the case results in a financial settlement for the investors.

To participate in the prospective lawsuit, investors can submit their information through the Rosen Law Firm's secure online form or contact Phillip Kim, Esq. directly via phone or email. Rosen Law Firm has a strong track record of success in handling such cases, emphasizing the importance of choosing qualified legal counsel with relevant experience.

Why Choose Rosen Law Firm?

Rosen Law Firm has established itself as a leading firm specializing in securities class actions and shareholder derivative litigation. The firm is recognized for achieving the largest securities class action settlement against a Chinese company at the time, and it has consistently been ranked among the top firms nationally for several years.

In 2019, the firm successfully recovered over $438 million for investors, showcasing its capability and determination in protecting investor rights. Founding member Laurence Rosen has been acknowledged by prominent legal publications and was named a Titan of the Plaintiffs' Bar by Law360 in 2020, asserting his expertise in the field.

With numerous attorneys within the firm being recognized by industry-leading platforms such as Lawdragon and Super Lawyers, the firm demonstrates a commitment to providing effective representation for its clients.

Keeping Informed and Connected

Investors are encouraged to stay informed on the developments of this investigation and any impending class action by following Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook. The firm remains dedicated to ensuring that investors affected by potentially misleading practices are transparently represented and compensated accordingly.

Potential investors wishing to learn more about the class action or share their experiences are urged to reach out to the Rosen Law Firm directly for guidance.

In the complex landscape of securities litigation, the experience and resources of Rosen Law Firm can be pivotal in the pursuit of justice for shareholders, making it an essential ally for those affected by the recent events surrounding Aldeyra Therapeutics.